• Anika Therapeutics entered a Fifth Amendment on July 10, 2026 to its revolving credit agreement with Bank of America.
• Amended Agreement keeps a USD 50 million senior revolving line of credit, extending maturity to July 10, 2031.
• Facility includes an accordion for up to USD 50 million, lifting potential total commitments to USD 100 million, subject to conditions.
• Borrowings price at SOFR plus 0.25% to 1.25%, tied to consolidated leverage; unused commitment fee set at 0.20% to 0.30%.
• Lenders hold a first-priority lien on substantially all assets, excluding certain intangible assets; financial covenants cap leverage and interest coverage ratios.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anika Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-004635), on July 14, 2026, and is solely responsible for the information contained therein.